Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | HPGD | P15428 | 3/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | QSOX1 | O00391 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4203044 | 0.98 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDGAAMEN1 | |
| SCHEMBL1490676 | 0.88 | PLOD2 (0.60) | ALDH1A1KDM4EHPGDGAAMEN1 | |
| SCHEMBL4250883 | 0.86 | KMO (0.68) | ALDH1A1HPGDGAAMEN1KMT2A | |
| SCHEMBL14696856 | 0.86 | ALDH1A1 (0.71) | ALDH1A1KDM4EHPGDGAAMEN1 | |
| SCHEMBL10145134 | 0.86 | GAA (0.54) | ALDH1A1KDM4EHPGDGAAMEN1 | |
| SCHEMBL2876503 | 0.86 | ADRB1 (0.59) | ALDH1A1KDM4EHPGDGAAMEN1 | |
| SCHEMBL22540807 | 0.86 | ALDH1A1 (0.49) | ALDH1A1KDM4EHPGDGAAMEN1 | |
| SCHEMBL21371829 | 0.85 | TSHR (0.58) | ALDH1A1KDM4EHPGDGAAMEN1 | |
| SCHEMBL134726 | 0.85 | F10 (0.52) | ALDH1A1KDM4EHPGDGAAMEN1 | |
| SCHEMBL10145136 | 0.85 | GAA (0.53) | ALDH1A1KDM4EHPGDGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381146-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2023-11-30 | — | — | US | disclosed |
| US-20230381146-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2023-11-30 | — | — | US | disclosed |
| US-20230381146-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2023-11-30 | — | — | US | disclosed |
| CN-116367832-A | Substituted heteroaryl compounds and uses thereof | 苏州华明道康生物医药有限公司 | 2023-06-30 | — | — | CN | disclosed |
| WO-2022078294-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| EP-2632255-B1 | DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-1358183-B1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| US-20050070598-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2005-03-31 | — | — | US | disclosed |
| US-20040229915-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2004-11-18 | — | — | US | disclosed |
| EP-1358183-A2 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| US-20030186962-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2003-10-02 | — | — | US | disclosed |
| WO-2002088106-A2 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186962-A1 | Cysteine protease inhibitors | C1R, CTSS, CTSZ | ALDH1A1 3348/4885KDM4E 2985/4885HPGD 2736/4885 |
| US-20050070598-A1 | Cysteine protease inhibitors | CTRL, CTSZ, CTSS | ALDH1A1 3475/4885KDM4E 2323/4885HPGD 2259/4885 |
| US-20230381146-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | SSB, BTK, PADI6 | ALDH1A1 1123/4885KDM4E 2480/4885HPGD 2296/4885 |
| US-20040229915-A1 | Cysteine protease inhibitors | C1R, CTRL, CTSK | ALDH1A1 3118/4885KDM4E 2958/4885HPGD 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.